MAP2K1 and non-small cell lung carcinoma: Our analysis of TCGA cohorts of NSCLC revealed that dysregulation and genetic alterations of the EGFR, MAP2K1, mTOR, and YAP1 signaling pathways were associated with the progression, therapeutic response, and worse prognosis of NSCLC.